Press Releases

04.19.2016

AM-Pharma STOP-AKI Phase II trial nominated for “Most Innovative Clinical Trial Design” in 2016 CARE Awards

04.19.2016

Pfizer Announces Positive Top-Line Results for Phase 3 PALOMA-2 Clinical Trial of IBRANCE® (palbociclib)

04.07.2016

Pfizer Taps IBM for Research Collaboration to Transform Parkinson’s Disease Care

04.06.2016

Pfizer Receives European Approval for New Multi-Dose Vial Presentation of Prevenar 13®

04.06.2016

Pfizer Announces Termination of Proposed Combination with Allergan

04.05.2016

FDA Approves INFLECTRA™ (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications

04.05.2016

Merck and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinom

04.05.2016

Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis

04.04.2016

Pfizer and Allergan Issue Statement

04.04.2016

Cancer Metabolism Company Metabomed Completes $18 Million Series A Financing

04.01.2016

Pfizer Announces Positive Topline Results from Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab

03.31.2016

Pfizer Inc. (NYSE: PFE) today issued the following statement: